New treatment guidelines for bladder cancer presented at the National Comprehensive Cancer Network Annual Conference
Thomas Flaig, M.D., from the CU Cancer Center and Director of Criterium’s Academic Urology Research Investigators Consortium (AURIC) discussed new treatment guidelines at the National Comprehensive Cancer Network annual conference.
Learn about the new treatment guidelines
Dr. Camidge reflects on his journey from doctor to patient
D. Ross Camidge, M.D., Ph.D., Senior Advisor of Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) discusses his career path, from spending a gap year working at McDonald’s to advancing solutions for lung cancer and his journey as a patient.
Learn about Dr. Camidge’s journey from doctor to patient
Designing an effective care plan for stage IV colon cancer
A woman diagnosed at 40 with stage IV colon cancer discusses her experience with CU Anschutz Cancer Center’s care and clinical trials, including the care plan designed by Wells Messersmith, M.D., Director of Criterium’s Academic GI Cancer Consortium (AGICC).
Learn more
Dr. Pusztai recognized as a Giant of Cancer Care by OncLive for significant contributions to cancer research
Congratulations to Lajos Pusztai, M.D., D.Phil. from Criterium’s Academic Breast Cancer Consortium (ABRCC) and the Yale Cancer Center for being named a Giant of Cancer Care®️ for Prevention & Genetics by OncLive.
Learn more about the award and Dr. Pusztai’s research
Emerging data on small cell lung cancer treatment
Laura Alder, MD, of Duke University Medical Center and Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), discusses emerging data on small cell lung cancer treatment, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate.
Watch Dr. Alder discuss the new research findings
Clinical trial shows novel prostate cancer treatment can significantly reduce risk of disease progression
A Phase 3 clinical trial led by Neeraj Agarwal, M.D., from the Huntsman Cancer Institute and Criterium’s Academic Urology Research Investigators Consortium (AURIC), found that a combination prostate cancer treatment could curb disease progression in some patients.
Learn more about the study results
Study finds molecular differences in young women’s breast cancer tumors
A study lead by Lajos Pusztai, M.D., D.Phil., from Criterium’s Academic Breast Cancer Consortium (ABRCC) and the Yale Cancer Center, aims to explain age-related response to chemotherapy, helping advance personalized medicine for women with breast cancer.
Learn about the study findings
